ILT-2 and ILT-4 expression and donor genotype as factors associated with HSCT outcome

ILT-2 and ILT-4 expression and donor genotype as factors associated with HSCT outcome

Copyright © 2025. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 281(2025) vom: 02. Okt., Seite 110605
Auteur principal: Siemaszko, Jagoda (Auteur)
Autres auteurs: Łacina, Piotr, Szymczak, Donata, Szeremet, Agnieszka, Majcherek, Maciej, Czyż, Anna, Sobczyk-Kruszelnicka, Małgorzata, Fidyk, Wojciech, Solarska, Iwona, Nasiłowska-Adamska, Barbara, Skowrońska, Patrycja, Bieniaszewska, Maria, Tomaszewska, Agnieszka, Basak, Grzegorz W, Giebel, Sebastian, Wróbel, Tomasz, Bogunia-Kubik, Katarzyna
Format: Article en ligne
Langue:English
Publié: 2025
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article GvHD HSCT ILT-2 ILT-4 NK cell receptors NK cells
LEADER 01000caa a22002652c 4500
001 NLM393607518
003 DE-627
005 20251008232107.0
007 cr uuu---uuuuu
008 251005s2025 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2025.110605  |2 doi 
028 5 2 |a pubmed25n1593.xml 
035 |a (DE-627)NLM393607518 
035 |a (NLM)41046108 
035 |a (PII)S1521-6616(25)00180-9 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Siemaszko, Jagoda  |e verfasserin  |4 aut 
245 1 0 |a ILT-2 and ILT-4 expression and donor genotype as factors associated with HSCT outcome 
264 1 |c 2025 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Revised 07.10.2025 
500 |a published: Print-Electronic 
500 |a Citation Status Publisher 
520 |a Copyright © 2025. Published by Elsevier Inc. 
520 |a BACKGROUND: NK cell activity after allogeneic haematopoietic stem cell transplantation (HSCT) is still not fully understood. Their cytotoxic activity is modulated by a range of inhibitory and activating surface receptors. Among these, the inhibitory receptors ILT-2 and ILT-4 have yet to be explored in relation to HSCT and its outcomes 
520 |a METHODS: Genotyping for ILT-2 and ILT-4 was performed using TaqMan assays. ILT-2 and ILT-4 surface expression on NK cells was assessed by flow cytometry. Levels of sHLA-F and sHLA-G were determined using ELISA. mRNA expression of ILT-2, ILT-4 and IFN-γ was measured with quantitative real-time PCR with TaqMan Gene Expression probes 
520 |a RESULTS: Presence of donor ILT-2 rs1061681 T allele was associated with increased risk of chronic graft-versus-host disease (cGVHD) (p = 0.0239). Donor ILT-4 rs1128646 T allele was related with decreased risk of overall survival after HSCT (p = 0.0506) and with higher risk of acute GvHD (aGvHD) (p = 0.0834). Serum levels of sHLA-F and sHLA-G were significantly higher at day +30 than day +90 after HSCT (p = 0.0002 and p < 0.0001, respectively). Expression of ILT2 at mRNA level was significantly decreased among recipients with aGvHD (p = 0.0266). ILT-4 expression correlated negatively with expression of interferon gamma (p = 0.0280, R = -0.532). The percentages of LILRB1/ILT-2+ and LILRB2/ILT4+ NK cells were the highest at day +21 after HSCT (p = 0.0014 and p < 0.0001 for ILT-2 and ILT-4, respectively) 
520 |a CONCLUSIONS: Both ILT-2 and ILT-4 inhibitory receptors were found to be associated with allogeneic HSCT outcome. This suggests that ILT receptor expression on NK cells may potentially play a role in post-transplant complications 
650 4 |a Journal Article 
650 4 |a GvHD 
650 4 |a HSCT 
650 4 |a ILT-2 
650 4 |a ILT-4 
650 4 |a NK cell receptors 
650 4 |a NK cells 
700 1 |a Łacina, Piotr  |e verfasserin  |4 aut 
700 1 |a Szymczak, Donata  |e verfasserin  |4 aut 
700 1 |a Szeremet, Agnieszka  |e verfasserin  |4 aut 
700 1 |a Majcherek, Maciej  |e verfasserin  |4 aut 
700 1 |a Czyż, Anna  |e verfasserin  |4 aut 
700 1 |a Sobczyk-Kruszelnicka, Małgorzata  |e verfasserin  |4 aut 
700 1 |a Fidyk, Wojciech  |e verfasserin  |4 aut 
700 1 |a Solarska, Iwona  |e verfasserin  |4 aut 
700 1 |a Nasiłowska-Adamska, Barbara  |e verfasserin  |4 aut 
700 1 |a Skowrońska, Patrycja  |e verfasserin  |4 aut 
700 1 |a Bieniaszewska, Maria  |e verfasserin  |4 aut 
700 1 |a Tomaszewska, Agnieszka  |e verfasserin  |4 aut 
700 1 |a Basak, Grzegorz W  |e verfasserin  |4 aut 
700 1 |a Giebel, Sebastian  |e verfasserin  |4 aut 
700 1 |a Wróbel, Tomasz  |e verfasserin  |4 aut 
700 1 |a Bogunia-Kubik, Katarzyna  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 281(2025) vom: 02. Okt., Seite 110605  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:281  |g year:2025  |g day:02  |g month:10  |g pages:110605 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2025.110605  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 281  |j 2025  |b 02  |c 10  |h 110605